The company plans a clinical trial for its CIL001 drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET.
With several completely implantable CIs in development, a new device choice for patients with severe-to-profound hearing loss is on the horizon.
The sponsorship anchors the new “Hear to Win” campaign, bringing hearing health education and technology demonstrations to pickleball events nationwide.
In a pivotal trial, 42% of participants achieved normal hearing using the gene therapy indicated for pediatric and adult patients with severe-to-profound hearing loss due to biallelic OTOF gene variants.
Developed by the National Acoustic Laboratories, the system builds on NAL-NL2 and is designed for more precise, personalized hearing aid fittings.
The ideal individual will discuss cost with patients in a way that builds trust, empowers decisions, and supports practice sustainability.
